WO2006029233A3 - Apparatus for prolonging survival of platelets - Google Patents

Apparatus for prolonging survival of platelets Download PDF

Info

Publication number
WO2006029233A3
WO2006029233A3 PCT/US2005/031921 US2005031921W WO2006029233A3 WO 2006029233 A3 WO2006029233 A3 WO 2006029233A3 US 2005031921 W US2005031921 W US 2005031921W WO 2006029233 A3 WO2006029233 A3 WO 2006029233A3
Authority
WO
WIPO (PCT)
Prior art keywords
platelets
prolonging survival
pharmaceutical composition
methods
platelet clearance
Prior art date
Application number
PCT/US2005/031921
Other languages
French (fr)
Other versions
WO2006029233A2 (en
WO2006029233A9 (en
Inventor
Keith Rosiello
Henrik Clausen
Original Assignee
Zymequest Inc
Keith Rosiello
Henrik Clausen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES05796386T priority Critical patent/ES2376777T3/en
Application filed by Zymequest Inc, Keith Rosiello, Henrik Clausen filed Critical Zymequest Inc
Priority to CA002621250A priority patent/CA2621250A1/en
Priority to EP05796386A priority patent/EP1796457B1/en
Priority to AT05796386T priority patent/ATE534290T1/en
Priority to JP2007530489A priority patent/JP5450958B2/en
Priority to AU2005282449A priority patent/AU2005282449B2/en
Priority to US11/574,857 priority patent/US8052667B2/en
Publication of WO2006029233A2 publication Critical patent/WO2006029233A2/en
Publication of WO2006029233A3 publication Critical patent/WO2006029233A3/en
Priority to US12/089,132 priority patent/US20120225044A9/en
Publication of WO2006029233A9 publication Critical patent/WO2006029233A9/en
Priority to US13/291,402 priority patent/US8517967B2/en
Priority to US13/946,711 priority patent/US20140154665A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Abstract

The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis.
PCT/US2005/031921 2004-09-07 2005-09-07 Apparatus for prolonging survival of platelets WO2006029233A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2005282449A AU2005282449B2 (en) 2004-09-07 2005-09-07 Apparatus for prolonging survival of platelets
CA002621250A CA2621250A1 (en) 2004-09-07 2005-09-07 Apparatus for prolonging survival of platelets
EP05796386A EP1796457B1 (en) 2004-09-07 2005-09-07 Apparatus for prolonging survival of platelets
AT05796386T ATE534290T1 (en) 2004-09-07 2005-09-07 APPARATUS FOR EXTENDING PLATELET SURVIVAL
JP2007530489A JP5450958B2 (en) 2004-09-07 2005-09-07 Compositions and methods for prolonging platelet survival
ES05796386T ES2376777T3 (en) 2004-09-07 2005-09-07 Apparatus for prolonging platelet survival
US11/574,857 US8052667B2 (en) 2004-09-07 2005-09-07 Apparatus for prolonging survival of platelets
US12/089,132 US20120225044A9 (en) 2004-09-07 2006-10-16 Compositions and methods for prolonging survival of platelets
US13/291,402 US8517967B2 (en) 2004-09-07 2011-11-08 Methods of using an apparatus for prolonging survival of platelets using CMP-sialic acid, UDP-galactose or both
US13/946,711 US20140154665A1 (en) 2004-09-07 2013-07-19 Apparatuses, Compositions, and Methods for Prolonging Survival of Platelets

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US60760004P 2004-09-07 2004-09-07
US60/607,600 2004-09-07
US61917604P 2004-10-15 2004-10-15
US60/619,176 2004-10-15
US67872405P 2005-05-06 2005-05-06
US60/678,724 2005-05-06

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US11/574,857 A-371-Of-International US8052667B2 (en) 2004-09-07 2005-09-07 Apparatus for prolonging survival of platelets
US11577261 Continuation-In-Part 2005-10-17
PCT/US2005/037241 Continuation-In-Part WO2006044790A2 (en) 2004-09-07 2005-10-17 Compositions and methods for prolonging survival of platelets
US13/291,402 Continuation US8517967B2 (en) 2004-09-07 2011-11-08 Methods of using an apparatus for prolonging survival of platelets using CMP-sialic acid, UDP-galactose or both

Publications (3)

Publication Number Publication Date
WO2006029233A2 WO2006029233A2 (en) 2006-03-16
WO2006029233A3 true WO2006029233A3 (en) 2006-10-05
WO2006029233A9 WO2006029233A9 (en) 2007-05-18

Family

ID=35759421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/031921 WO2006029233A2 (en) 2004-09-07 2005-09-07 Apparatus for prolonging survival of platelets

Country Status (8)

Country Link
US (3) US8052667B2 (en)
EP (1) EP1796457B1 (en)
JP (2) JP5450958B2 (en)
AT (1) ATE534290T1 (en)
AU (1) AU2005282449B2 (en)
CA (1) CA2621250A1 (en)
ES (1) ES2376777T3 (en)
WO (1) WO2006029233A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003290677B2 (en) 2002-11-08 2009-09-17 The Brigham And Women's Hospital, Inc. Compositions and methods for prolonging survival of platelets
WO2006029233A2 (en) * 2004-09-07 2006-03-16 Zymequest, Inc. Apparatus for prolonging survival of platelets
DE602005026043D1 (en) * 2004-10-15 2011-03-03 Velico Medical Inc COMPOSITIONS AND METHODS FOR EXTENDING THE SURVIVAL OF BLOODPLATES
JP5552231B2 (en) * 2005-10-14 2014-07-16 ベリコ メディカル インコーポレイティッド Compositions and methods for prolonging platelet survival
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
EP2211046B1 (en) * 2008-12-29 2011-03-02 C.R.F. Società Consortile per Azioni Fuel injection system with high repeatability and stability of operation for an internal-combustion engine
US8834402B2 (en) 2009-03-12 2014-09-16 Haemonetics Corporation System and method for the re-anticoagulation of platelet rich plasma
WO2012060848A1 (en) 2010-11-05 2012-05-10 Haemonetics Corporation System and method for automated platelet wash
US9302042B2 (en) 2010-12-30 2016-04-05 Haemonetics Corporation System and method for collecting platelets and anticipating plasma return
CN103702557A (en) 2011-03-16 2014-04-02 梅奥医学教育和研究基金会 Methods and materials for prolonging useful storage of red blood cell preparations and platelet preparations
CN103702556A (en) 2011-05-17 2014-04-02 维利科医疗公司 Improved platelet storage using a sialidase inhibitor
US9788539B2 (en) 2011-05-17 2017-10-17 Velico Medical, Inc. Platelet protection solution having beta-galactosidase and sialidase inhibitors
EP2806914B1 (en) 2012-01-23 2021-09-22 Estar Technologies Ltd A system and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma(prp)
EP2903430A1 (en) 2012-10-05 2015-08-12 Velico Medical, Inc. Platelet additive solution having a beta-galactosidase inhibitor
WO2014120886A1 (en) 2013-01-30 2014-08-07 Velico Medical, Inc. Platelet additive solution having a self-assembling hydrogel-forming peptide
US10159778B2 (en) 2014-03-24 2018-12-25 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US9796166B2 (en) 2014-03-24 2017-10-24 Fenwal, Inc. Flexible biological fluid filters
US9968738B2 (en) 2014-03-24 2018-05-15 Fenwal, Inc. Biological fluid filters with molded frame and methods for making such filters
US10376627B2 (en) 2014-03-24 2019-08-13 Fenwal, Inc. Flexible biological fluid filters
US9782707B2 (en) 2014-03-24 2017-10-10 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
WO2016164693A1 (en) 2015-04-10 2016-10-13 Board Of Regents, The University Of Texas System Compositions and methods for prolonged cell storage
US20220088589A1 (en) 2019-01-21 2022-03-24 Eclipse Medcorp, Llc Methods, Systems and Apparatus for Separating Components of a Biological Sample
WO2021224401A1 (en) 2020-05-07 2021-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for determining a reference range of β-galactose exposure platelet
CN111937860B (en) * 2020-08-17 2021-11-09 无锡市人民医院 Isolated organ perfusion system

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344936A (en) * 1980-09-17 1982-08-17 Gerald Soslau Platelet composition having improved storage stability and method therefor
US4432750A (en) * 1981-12-02 1984-02-21 Baxter Travenol Laboratories, Inc. Additive sterol solution and method for preserving normal red cell morphology in whole blood during storage
WO1998041087A1 (en) * 1997-03-17 1998-09-24 Baxter International Inc. Red blood cell compositions and methods for collecting and storing red blood cells
WO2002016381A2 (en) * 2000-08-21 2002-02-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US20030104349A1 (en) * 2001-12-05 2003-06-05 Baxter International Inc. Manual processing systems and methods for providing blood components conditioned for pathogen inactivation

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407660A (en) * 1981-09-08 1983-10-04 Baxter Travenol Laboratories, Inc. Plasmapheresis assembly and associated fluid manifold
US4467588A (en) * 1982-04-06 1984-08-28 Baxter Travenol Laboratories, Inc. Separated packaging and sterile processing for liquid-powder mixing
US4412835A (en) 1982-07-06 1983-11-01 E. I. Du Pont De Nemours & Company Sterile docking process, apparatus and system
DE3578502D1 (en) * 1984-03-15 1990-08-09 Asahi Medical Co FILTER UNIT FOR SEPARATING LEUKOCYTES.
US4610684A (en) * 1984-06-22 1986-09-09 Abbott Laboratories Flexible container and mixing system for storing and preparing I.V. fluids
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4994039A (en) * 1985-11-15 1991-02-19 Mattson Philip D Apparatus and method for patients from a single donor or a restricted group of donors
US4915848A (en) * 1986-04-21 1990-04-10 Miles Laboratories, Inc. Red blood cell filtering system
US5344561A (en) * 1989-05-09 1994-09-06 Pall Corporation Device for depletion of the leucocyte content of blood and blood components
US6518051B1 (en) * 1991-04-11 2003-02-11 The Trustees Of The University Of Pennsylvania Saccharide compositions, methods and apparatus for their synthesis
WO1992022563A1 (en) * 1991-06-10 1992-12-23 Alberta Research Council Modified sialyl lewisa compounds
US5910252A (en) * 1993-02-12 1999-06-08 Cobe Laboratories, Inc. Technique for extracorporeal treatment of blood
US5358844A (en) * 1993-02-18 1994-10-25 Brigham And Women's Hospital, Inc. Preservation of blood platelets
US5919614A (en) * 1994-10-19 1999-07-06 Lifecell Corporation Composition comprising three platelet lesion inhibitors for platelet storage
US5691132A (en) * 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
JPH0967270A (en) 1995-08-31 1997-03-11 Res Dev Corp Of Japan Prevention and therapy for opacity of crystalline lens and medicine therefor
DE69637625D1 (en) * 1995-10-19 2008-09-18 Bio Origyn Llc METHODS AND COMPOSITIONS THAT IMPROVE THE SURVIVAL AND FUNCTION OF GERMAN CELLS AND EMBRYOS
US6743575B2 (en) * 1996-06-14 2004-06-01 Biostore New Zealand Ltd. Compositions and methods for the preservation of living tissues
US6413713B1 (en) * 1998-10-30 2002-07-02 Hyperbaric Systems Method for preserving blood platelets
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US7651474B2 (en) * 1999-10-01 2010-01-26 Caridianbct, Inc. Method and apparatus for leukoreduction of red blood cells
CA2417574A1 (en) * 2000-07-28 2002-02-07 National Research Council Of Canada Modified sialic acid vaccines
US20030224486A1 (en) * 2001-04-19 2003-12-04 Julie Carman Polynucleotides and polypeptides associated with the NF-kB pathway
NZ531093A (en) 2001-08-17 2007-12-21 Neose Technologies Inc Chemo-enzymatic synthesis of sialylated oligosaccharides
AU2002336761A1 (en) * 2001-09-26 2003-04-07 The Government Of The United States Of America, Represented By The Secretary, Department Of Health A Nitric oxide-releasing coated medical devices and method of preparing same
ES2556338T3 (en) * 2001-10-10 2016-01-15 Novo Nordisk A/S Remodeling and glycoconjugation of peptides
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
WO2003089926A2 (en) * 2002-04-19 2003-10-30 Mission Medical, Inc. Integrated automatic blood processing unit
US20040071686A1 (en) 2002-04-25 2004-04-15 Treco Douglas A. Treatment of alpha-galactosidase A deficiency
JP4510938B2 (en) * 2002-07-15 2010-07-28 イミュネックス・コーポレーション Method and medium for regulating sialic acid addition of proteins produced by mammalian cells
AU2003290677B2 (en) 2002-11-08 2009-09-17 The Brigham And Women's Hospital, Inc. Compositions and methods for prolonging survival of platelets
WO2006029233A2 (en) * 2004-09-07 2006-03-16 Zymequest, Inc. Apparatus for prolonging survival of platelets
DE602005026043D1 (en) * 2004-10-15 2011-03-03 Velico Medical Inc COMPOSITIONS AND METHODS FOR EXTENDING THE SURVIVAL OF BLOODPLATES
JP5552231B2 (en) 2005-10-14 2014-07-16 ベリコ メディカル インコーポレイティッド Compositions and methods for prolonging platelet survival
CN106008699A (en) * 2006-09-08 2016-10-12 Ambrx公司 Modified human plasma polypeptide or Fc scaffolds and their uses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344936A (en) * 1980-09-17 1982-08-17 Gerald Soslau Platelet composition having improved storage stability and method therefor
US4432750A (en) * 1981-12-02 1984-02-21 Baxter Travenol Laboratories, Inc. Additive sterol solution and method for preserving normal red cell morphology in whole blood during storage
WO1998041087A1 (en) * 1997-03-17 1998-09-24 Baxter International Inc. Red blood cell compositions and methods for collecting and storing red blood cells
WO2002016381A2 (en) * 2000-08-21 2002-02-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US20030104349A1 (en) * 2001-12-05 2003-06-05 Baxter International Inc. Manual processing systems and methods for providing blood components conditioned for pathogen inactivation

Also Published As

Publication number Publication date
US8517967B2 (en) 2013-08-27
EP1796457A2 (en) 2007-06-20
CA2621250A1 (en) 2006-03-16
US8052667B2 (en) 2011-11-08
WO2006029233A2 (en) 2006-03-16
JP2008512388A (en) 2008-04-24
JP5450958B2 (en) 2014-03-26
ES2376777T3 (en) 2012-03-16
US20080199845A1 (en) 2008-08-21
AU2005282449B2 (en) 2011-07-14
AU2005282449A1 (en) 2006-03-16
WO2006029233A9 (en) 2007-05-18
US20140154665A1 (en) 2014-06-05
US20120107791A1 (en) 2012-05-03
ATE534290T1 (en) 2011-12-15
JP2013227329A (en) 2013-11-07
EP1796457B1 (en) 2011-11-23

Similar Documents

Publication Publication Date Title
WO2006029233A3 (en) Apparatus for prolonging survival of platelets
WO2006044790A3 (en) Compositions and methods for prolonging survival of platelets
WO2004043381A3 (en) Compositions and methods for prolonging survival of platelets
WO2007047687A3 (en) Compositions and methods for prolonging survival of platelets
UA96449C2 (en) Stable laquinimod preparations
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
EP1610742A4 (en) Methods and compositions for administration of trpv1 agonists
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2007056021A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
EP2021797A4 (en) Compositions of n-ý2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl¨-1,4-dihydro-4-oxoquinoline-3-carboxamide
SG156613A1 (en) Use of mitochondrially targeted antioxidant in the treatment of liver diseases and epithelial cancers
WO2007066337A3 (en) Jasmonate derivatives, pharmaceutical compositions and methods of use thereof
WO2007056228A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2008013840A3 (en) Erastin analogs and uses thereof
EP1858513A4 (en) Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
WO2006130703A3 (en) Modified release formulations of anti-irritability drugs
IL186050A0 (en) Novel isoindole derivatives, compositions containing same, preparation thereof and pharmaceutical uses thereof in particular as inhibitors of chaperone protein hsp90 activities
PL1853303T3 (en) Stabilized compositions for topical administration and methods of making same
WO2008061108A3 (en) Phthalazine derivatives
WO2006133006A3 (en) 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
IL179530A0 (en) Novel compounds, pharmaceutical compositions containing same and methods of use for same
WO2007139833A3 (en) Imidazoazephinone compounds
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007530489

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005282449

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005796386

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005282449

Country of ref document: AU

Date of ref document: 20050907

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005282449

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005796386

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11574857

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2621250

Country of ref document: CA